

A Brett Hauber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8679274/publications.pdf>

Version: 2024-02-01

110
papers

5,072
citations

172457

29
h-index

98798

67
g-index

111
all docs

111
docs citations

111
times ranked

4806
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1449-1458.	2.2	22
2	Assessing Payersâ€™ Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment. <i>Value in Health</i> , 2022, 25, 443-450.	0.3	4
3	Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis. <i>European Journal of Pain</i> , 2022, 26, 648-667.	2.8	7
4	The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United States. <i>AIDS Research and Therapy</i> , 2022, 19, 13.	1.7	2
5	Multimethod quantitative benefitâ€risk assessment of treatments for moderateâ€toâ€severe osteoarthritis. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	2.4	4
6	The Patient Voice: Exploring Treatment Preferences in Participants with Mild Cognitive Concerns to Inform Regulatory Decision Making. <i>Patient</i> , 2022, , .	2.7	2
7	Improvements to Survey Design from Pilot Testing a Discrete-Choice Experiment of the Preferences of Persons Living with HIV for Long-Acting Antiretroviral Therapies. <i>Patient</i> , 2022, 15, 513-520.	2.7	6
8	Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study. <i>Haemophilia</i> , 2021, 27, 129-136.	2.1	27
9	Quantitative Benefitâ€Risk Assessment: State of the Practice Within Industry. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 415-425.	1.6	13
10	Impact of clinical and demographic characteristics on patient preferences for psoriasis treatment features: Results from a discrete-choice experiment in a multicountry study. <i>Journal of Dermatological Treatment</i> , 2021, , 1-8.	2.2	3
11	A revealed preference analysis to develop composite scores approximating lung allocation policy in the U.S. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 8.	3.0	8
12	Communicating Test Results from a General Health Check: Preferences from a Discrete Choice Experiment Survey. <i>Patient</i> , 2021, 14, 649-660.	2.7	1
13	Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia. <i>Frontiers in Medicine</i> , 2021, 8, 595797.	2.6	8
14	Treatment preferences for preventive interventions for rheumatoid arthritis: protocol of a mixed methods case study for the Innovative Medicines Initiative PREFER project. <i>BMJ Open</i> , 2021, 11, e045851.	1.9	8
15	Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey. <i>Haemophilia</i> , 2021, 27, 957-966.	2.1	14
16	CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion. <i>Future Oncology</i> , 2021, 17, 4697-4709.	2.4	2
17	Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinsonâ€™s Disease. <i>MDM Policy and Practice</i> , 2021, 6, 238146832110213.	0.9	7
18	Parkinsonâ€™s Patientsâ€™ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study. <i>MDM Policy and Practice</i> , 2021, 6, 238146832097840.	0.9	12

#	ARTICLE	IF	CITATIONS
19	Artificial intelligence in breast cancer screening: primary care provider preferences. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1117-1124.	4.4	19
20	Exploring Decisional Conflict With Measures of Numeracy and Optimism in a Stated Preference Survey. MDM Policy and Practice, 2021, 6, 238146832110586.	0.9	0
21	Design and evaluation of strategies to implement HIV prevention interventions for pregnant women in community pharmacy settings in western Kenya: a mixed-methods study protocol. BMJ Open, 2021, 11, e052311.	1.9	1
22	Using the Threshold Technique to Elicit Patient Preferences: An Introduction to the Method and an Overview of Existing Empirical Applications. Applied Health Economics and Health Policy, 2020, 18, 31-46.	2.1	31
23	Quantifying what matters most to patients and care partners in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e040095.	0.8	1
24	Evaluation of what matters most in existing clinical outcomes assessments in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e040100.	0.8	1
25	<p>The Value of Hope: Patientsâ€™ and Physiciansâ€™ Preferences for Survival in Advanced Non-Small Cell Lung Cancer</p>. Patient Preference and Adherence, 2020, Volume 14, 2093-2104.	1.8	9
26	Modeling Heterogeneity in Patientsâ€™ Preferences for Psoriasis Treatments in a Multicountry Study: A Comparison Between Random-Parameters Logit and Latent Class Approaches. Pharmacoeconomics, 2020, 38, 593-606.	3.3	17
27	<p>Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia</p>. Patient Preference and Adherence, 2020, Volume 14, 1049-1064.	1.8	1
28	Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA. Rheumatology and Therapy, 2019, 6, 461-471.	2.3	52
29	<p>Patient and physician preferences for ulcerative colitis treatments in the United States</p>. Clinical and Experimental Gastroenterology, 2019, Volume 12, 263-278.	2.3	27
30	<p>From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices</p>. Patient Preference and Adherence, 2019, Volume 13, 1093-1110.	1.8	8
31	Conducting a Discrete-Choice Experiment Study Following Recommendations for Good Research Practices: An Application for Eliciting Patient Preferences for Diabetes Treatments. Value in Health, 2018, 21, 59-68.	0.3	51
32	Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey. Supportive Care in Cancer, 2018, 26, 251-260.	2.2	12
33	Preferences for vaccines against childrenâ€™s diarrheal illness among mothers in Poland and Hungary. Vaccine, 2018, 36, 6022-6029.	3.8	13
34	Comparison of US patient, rheumatologist, and dermatologist perceptions of psoriatic disease symptoms: results from the DISCONNECT study. Arthritis Research and Therapy, 2018, 20, 102.	3.5	15
35	Colorectal Cancer Screening: Preferences, Past Behavior, and Future Intentions. Patient, 2018, 11, 599-611.	2.7	18
36	Physiciansâ€™ preferences for bone metastases treatments in France, Germany and the United Kingdom. BMC Health Services Research, 2018, 18, 518.	2.2	5

#	ARTICLE	IF	CITATIONS
37	Benefit-risk tradeoff preferences for chronic hand eczema treatments. Journal of Dermatological Treatment, 2017, 28, 40-46.	2.2	6
38	Weighing Clinical Evidence Using Patient Preferences: An Application of Probabilistic Multi-Criteria Decision Analysis. Pharmacoeconomics, 2017, 35, 259-269.	3.3	12
39	The Ball is in Your Court: Agenda for Research to Advance the Science of Patient Preferences in the Regulatory Review of Medical Devices in the United States. Patient, 2017, 10, 531-536.	2.7	18
40	Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability?. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 531-542.	1.4	88
41	Quantifying the relative importance to patients of avoiding symptoms and outcomes of heart failure. Current Medical Research and Opinion, 2017, 33, 2027-2038.	1.9	3
42	Hemodialysis patients' preferences for the management of anemia. BMC Nephrology, 2017, 18, 253.	1.8	7
43	Hemodialysis patients' preferences for the management of secondary hyperparathyroidism. BMC Nephrology, 2017, 18, 254.	1.8	10
44	Quantifying the importance of inhaler attributes corresponding to items in the patient satisfaction and preference questionnaire in patients using Combivent Respimat. Health and Quality of Life Outcomes, 2017, 15, 201.	2.4	9
45	Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. Cancer Management and Research, 2017, Volume 9, 149-158.	1.9	15
46	Preferences for Multiple Sclerosis Treatments. International Journal of MS Care, 2017, 19, 172-183.	1.0	23
47	Stated Preference for Cancer Screening: A Systematic Review of the Literature, 1990-2013. Preventing Chronic Disease, 2016, 13, E27.	3.4	54
48	Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trials. Patient Preference and Adherence, 2016, Volume 10, 2127-2139.	1.8	22
49	A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies. Value in Health, 2016, 19, 746-750.	0.3	106
50	Patients' Self-Reported Value of Avoiding Key Heart Failure Outcomes Differs Based on Disease Knowledge. Journal of Cardiac Failure, 2016, 22, S100.	1.7	1
51	The effect of information on preferences for treatments of metastatic renal cell carcinoma. Current Medical Research and Opinion, 2016, 32, 1827-1838.	1.9	8
52	Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors. Patient, 2016, 9, 323-333.	2.7	11
53	Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value in Health, 2016, 19, 300-315.	0.3	782
54	A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Current Medical Research and Opinion, 2016, 32, 251-262.	1.9	46

#	ARTICLE	IF	CITATIONS
55	Estimating conditional certainty equivalents using choice-experiment data. <i>Journal of Choice Modelling</i> , 2015, 15, 14-25.	2.3	2
56	Estimating the value of medical treatments to patients using probabilistic multi criteria decision analysis. <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 102.	3.0	15
57	Physiciansâ€™ Preferences for Bone Metastases Drug Therapy in the United States. <i>Value in Health</i> , 2015, 18, 78-83.	0.3	22
58	A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2015, 6, 75-84.	2.5	32
59	Incorporating patient-preference evidence into regulatory decision making. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 2984-2993.	2.4	182
60	Psoriasis patientsâ€™ willingness to accept side-effect risks for improved treatment efficacy. <i>Journal of Dermatological Treatment</i> , 2015, 26, 507-513.	2.2	22
61	Comparing Patient and Physician Risk Tolerance for Bleeding Events Associated with Anticoagulants in Atrial Fibrillationâ€”evidence from the United States and Japan. <i>Value in Health Regional Issues</i> , 2015, 6, 65-72.	1.2	18
62	Too many attributes: A test of the validity of combining discrete-choice and bestâ€”worst scaling data. <i>Journal of Choice Modelling</i> , 2015, 15, 1-13.	2.3	19
63	Patientsâ€™ preferences for bone metastases treatments in France, Germany and the United Kingdom. <i>Supportive Care in Cancer</i> , 2015, 23, 21-28.	2.2	33
64	Patient preferences for treatments to delay bone metastases. <i>Prostate</i> , 2014, 74, 1488-1497.	2.3	20
65	Patients' Willingness to Trade Off Between the Duration and Frequency of Rheumatoid Arthritis Treatments. <i>Arthritis Care and Research</i> , 2014, 66, 1008-1015.	3.4	30
66	Understanding the relative importance of preserving functional abilities in Alzheimerâ€™s disease in the United States and Germany. <i>Quality of Life Research</i> , 2014, 23, 1813-1821.	3.1	23
67	Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives. <i>Current Medical Research and Opinion</i> , 2014, 30, 1733-1741.	1.9	27
68	Japanese Patientsâ€™ and Physiciansâ€™ Preferences for Anticoagulant Use in Atrial Fibrillation: Results from a Discrete-choice Experiment. <i>Journal of Health Economics and Outcomes Research</i> , 2014, 2, 207-220.	1.2	2
69	Quantifying Benefitâ€”Risk Preferences for Medical Interventions: An Overview of a Growing Empirical Literature. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 319-329.	2.1	106
70	Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes. <i>Patient Preference and Adherence</i> , 2013, 7, 937.	1.8	42
71	Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma. <i>Journal of Medical Economics</i> , 2012, 15, 1139-1148.	2.1	36
72	How Do Physicians Weigh Benefits and Risks Associated with Treatments in Patients with Osteoarthritis in the United Kingdom?. <i>Journal of Rheumatology</i> , 2012, 39, 1056-1063.	2.0	22

#	ARTICLE	IF	CITATIONS
73	Patients'™ preferences for treatment outcomes for advanced non-small cell lung cancer: A conjoint analysis. Lung Cancer, 2012, 77, 224-231.	2.0	119
74	Patients'™ Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection. Patient, 2012, 5, 265-278.	2.7	12
75	Physicians'™ stated trade-off preferences for chronic hepatitis B treatment outcomes in Germany, France, Spain, Turkey, and Italy. European Journal of Gastroenterology and Hepatology, 2012, 24, 1.	1.6	9
76	Patients'¼ Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection. Patient, 2012, 5, 265-278.	2.7	12
77	Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma. Pharmacoeconomics, 2011, 29, 977-988.	3.3	44
78	Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value in Health, 2011, 14, 403-413.	0.3	1,342
79	Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST). Patient Preference and Adherence, 2011, 5, 307.	1.8	15
80	Patient preferences and assessment of likely adherence to hepatitis C virus treatment. Journal of Viral Hepatitis, 2011, 18, 619-627.	2.0	34
81	Eliciting Benefit—Risk Preferences and Probability-Weighted Utility Using Choice-Format Conjoint Analysis. Medical Decision Making, 2011, 31, 469-480.	2.4	53
82	The value to patients of reducing lesion severity in plaque psoriasis. Journal of Dermatological Treatment, 2011, 22, 266-275.	2.2	27
83	Economic evaluation of OROS® hydromorphone for chronic pain: A Pan-European perspective. Journal of Opioid Management, 2011, 7, 287-296.	0.5	2
84	Who pays attention in stated—choice surveys?. Health Economics (United Kingdom), 2010, 19, 111-118.	1.7	22
85	Estimating importance weights for the IWQOL-Lite using conjoint analysis. Quality of Life Research, 2010, 19, 701-709.	3.1	23
86	Using the Incremental Net Benefit Framework for Quantitative Benefit—Risk Analysis in Regulatory Decision-Making—A Case Study of Alosetron in Irritable Bowel Syndrome. Value in Health, 2010, 13, 411-417.	0.3	27
87	Quantifying Women's Stated Benefit—Risk Trade-Off Preferences for IBS Treatment Outcomes. Value in Health, 2010, 13, 418-423.	0.3	33
88	Are Gastroenterologists Less Tolerant of Treatment Risks than Patients? Benefit-Risk Preferences in Crohn's Disease Management. Journal of Managed Care Pharmacy, 2010, 16, 616-628.	2.2	61
89	Patients' Benefit-Risk Preferences for Chronic Idiopathic Thrombocytopenic Purpura Therapies. Annals of Pharmacotherapy, 2010, 44, 479-488.	1.9	17
90	Conjoint Analysis Applications in Health — How are Studies being Designed and Reported?. Patient, 2010, 3, 249-256.	2.7	272

#	ARTICLE	IF	CITATIONS
91	Patient Preferences and Linear Scoring Rules for Patient-Reported Outcomes. <i>Patient</i> , 2010, 3, 217-227.	2.7	19
92	Healthy-years equivalent: wounded but not yet dead. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 265-269.	1.4	16
93	Benefits, Risk, and Uncertainty: Preferences of Antiretroviral-Naïve African Americans for HIV Treatments. <i>AIDS Patient Care and STDs</i> , 2009, 23, 29-34.	2.5	30
94	Evaluation of the relative importance of chemotherapeutic and antiemetic efficacy in various oncologic settings. <i>Supportive Care in Cancer</i> , 2009, 17, 405-411.	2.2	11
95	Using Conjoint Analysis to Estimate Healthy-Year Equivalents for Acute Conditions: An Application to Vasomotor Symptoms. <i>Value in Health</i> , 2009, 12, 146-152.	0.3	23
96	Hypothetical bias, cheap talk, and stated willingness to pay for health care. <i>Journal of Health Economics</i> , 2009, 28, 894-901.	2.7	88
97	Quantifying asthma patient preferences for onset of effect of combination inhaled corticosteroids and long-acting beta ₂ -agonist maintenance medications. <i>Allergy and Asthma Proceedings</i> , 2009, 30, 139-147.	2.2	24
98	Older Americans' Risk-benefit Preferences for Modifying the Course of Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 23-32.	1.3	27
99	Issues that May Affect the Validity and Reliability of Willingness-to-Pay Estimates in Stated-Preference Studies. <i>Patient</i> , 2008, 1, 249-250.	2.7	8
100	Patients Are Willing to Trade off Efficacy, Safety, and Administration Attributes of Chronic Idiopathic Purpura (ITP) Therapy: Results from a Large North American Discrete Choice Study. <i>Blood</i> , 2008, 112, 669-669.	1.4	2
101	Women's Willingness to Accept Perceived Risks for Vasomotor Symptom Relief. <i>Journal of Women's Health</i> , 2007, 16, 1028-1040.	3.3	23
102	Factors That Affect Adherence to Bipolar Disorder Treatments. <i>Medical Care</i> , 2007, 45, 545-552.	2.4	124
103	Stated Preferences of Patients with Cancer for Health-related Quality-of-life (HRQOL) Domains During Treatment. <i>Quality of Life Research</i> , 2006, 15, 273-283.	3.1	59
104	Are Chemotherapy Patients' HRQoL Importance Weights Consistent with Linear Scoring Rules? A Stated-choice Approach. <i>Quality of Life Research</i> , 2006, 15, 285-298.	3.1	42
105	Risking Health to Avoid Injections: Preferences of Canadians with type 2 diabetes. <i>Diabetes Care</i> , 2005, 28, 2243-2245.	8.6	48
106	The relationship between health perception and utility in heart failure patients in a clinical trial: results from an OVERTURE substudy. <i>Journal of Cardiac Failure</i> , 2004, 10, 339-343.	1.7	14
107	Stated preferences of patients with cancer for health-related quality-of-life domains during treatment. <i>Clinical Therapeutics</i> , 2003, 25, D22-D24.	2.5	0
108	The Effect of Nesting Structure Specification on Welfare Estimation in a Random Utility Model of Recreation Demand: An Application to the Demand for Recreational Fishing. <i>American Journal of Agricultural Economics</i> , 2000, 82, 501-514.	4.3	25

#	ARTICLE	IF	CITATIONS
109	Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine. Clinical Therapeutics, 2000, 22, 439-451.	2.5	59
110	Considerations Around Coding the Membership Probability Function in a Latent Class Analysis: Renewed Insights. Pharmacoeconomics, 0, , .	3.3	0